Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Rheumatoid Arthritis (RA)"

Clinical Criteria for RA & Early Non-Response to Certolizumab as Predictors of Patient Outcomes

Lara C. Pullen, PhD  |  May 25, 2020

A recent study compared three clinical criteria for rheumatoid arthritis (RA) in patients using certolizumab, assessing the predictability of treatment non-response. Researchers found Clinical Disease Activity Index measurement at three months may predict patient outcomes at 12 months…

Local Depletion of Resident Memory T Cells May Reduce Site-Specific Joint Flares

Carina Stanton  |  April 21, 2020

A study found resident memory T cells may mediate inflammatory arthritis and trigger flares in specific joints, suggesting local depletion of these cells could be a therapeutic strategy…

Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib

Lisa Rapaport  |  April 21, 2020

(Reuters Health)—The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests. Current ACR guidelines conditionally recommend that patients with RA who are 50 years and older be vaccinated against herpes zoster prior to starting therapy with the Janus kinase (JAK) inhibitor tofacitinib or…

New Research Identifies Possible Preclinical Rheumatoid Arthritis Biomarkers

Mike Fillon  |  March 19, 2020

ATLANTA—A key goal for rheumatology researchers and clinicians is to predict through specific biomarkers if someone will, at some point in their future, develop rheumatoid arthritis (RA). If so, the disease could be prevented or stopped before the inflammation and ravaging begins, explained researchers during a Basic Science lecture at the 2019 ACR/ARP Annual Meeting…

Strong Support for Treat-to-Target Strategy in RA Patients

Megan Brooks  |  March 16, 2020

NEW YORK (Reuters Health)—In daily clinical practice, following a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) leads to higher rates of remission compared with not following a T2T strategy, according to a longitudinal analysis of real world data. “The results of the analysis provide direct evidence that following T2T, and particularly sustained T2T,…

Epidemiology of Rheumatoid Arthritis May Be Changing

Will Boggs, MD  |  March 3, 2020

NEW YORK (Reuters Health)’Over the last three decades, there has been a significant decline in the incidence of rheumatoid factor (RF) positive rheumatoid arthritis (RA), while the overall incidence of RA has remained about the same, researchers report. “These trends may suggest changing serological profile of RA over time which may have implications for RA…

Phase 3 Results for Olokizumab in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  March 3, 2020

In a recent study, olokizumab proved safe and effective for treating the signs and symptoms of RA and improving patients’ physical function…

How Autoimmune & Non-Autoimmune Family Conditions Predict Rheumatoid Arthritis

Carina Stanton  |  March 3, 2020

New research has incorporated confounders, such as smoking, to build a clearer picture of family-related factors that may help predict who will develop rheumatoid arthritis…

According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA

Reuters Staff  |  February 5, 2020

NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….

Canada & E.U. Approve Upadacitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  January 28, 2020

Upadacitinib will soon be available to treat patients with moderate to severe rheumatoid arthritis in Canada and the E.U…

  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 30
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences